Frontlight ResearchEarly access
CompletedPhase 4
Solriamfetol and CBT-I in Patients With Insomnia Disorder
Key facts
- Who runs it
- University of Pennsylvania
- Where
- Philadelphia, United StatesSee the site
- Trial code
- Status
- Completed
- Phase
- Phase 4
- People taking part
- 115 people enrolled
- Started
- 31 Jul 2023
- Ended
- 30 Apr 2026
- Type of study
- Interventional, 4 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Solriamfetol 75 MG
- Cognitive Behavioral Therapy for Insomnia (CBT-I)
- Monitoring
- Placebo
- Record updated
- 12 May 2026
Who can take part
- Age
- 25 years to 60 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 20 criteriaShow less
Who can take part
- Participants will meet the diagnostic criteria for Insomnia Disorder according to Diagnostic and Statistical Manual of Mental Disorders (DSM-5); In addition, the complaint of disturbed sleep will meet the following criteria:
- ≥ 30 minutes to fall asleep (SL) and/or ≥ 2 awakenings per night of ≥ 15 minutes duration and/or wake after sleep onset (WASO) time of ≥ 30 minutes where total sleep time (TST) did not exceed 6 hours (unless sleep efficiency [SE] is ≤ 80%)
- The problem is present for > 3 nights per week
- The problem duration exceeds ≥ 6 months
- The complaint of impaired daytime function must include, although not limited to, the report of daytime fatigue, sleepiness, or both
- Preferred regular sleep phase between 10:00 PM and 8:00 AM
- Must garner physician's assent from their primary care clinician
Who cannot take part
- Use of medication expressly for the purpose of falling or staying asleep (e.g., trazodone/ desyrel, melatonin, Tylenol PM, Nyquil, Benadryl)
- Use of CNS active medications that are for treatment of insomnia or are thought to have caused insomnia as a side effect
- Major Coronary Artery Disease and/or uncontrolled (with meds) Hypertension
- Unstable medical or psychiatric illness
- Symptoms suggestive of sleep disorders other than insomnia
- Polysomnographic data indicating sleep disorders other than insomnia
- Night shift work
- Compromised renal function
- Planning to become pregnant, pregnant, and/or breastfeeding
- Evidence of active illicit substance use, abuse, or dependence
- Inadequate language comprehension
- Current or past experience with CBT-I
- No access to the computers, I-Pads, or the internet
Where in United States
- University Of Pennsylvania, Behavioral Sleep Medicine ProgramPhiladelphia, United States
About the trial
What the trial wants to find out
Medication is FDA approved. The objective of this project is to test the efficacy of solriamfetol for treating insomnia (alone and in combination with Cognitive Behavioral Therapy for Insomnia [CBT-I]). Ultimately, this study will test whether wake extension (regardless of how it is achieved) will consolidate sleep and improve sleep continuity.
The 4 groups in the trial
- Solriamfetol+ CBT-ITreatment being tested
Treatment: Solriamfetol 75 MG and Cognitive Behavioral Therapy for Insomnia (CBT-I)
- Solriamfetol OnlyTreatment being tested
Treatment: Solriamfetol 75 MG and Monitoring
- Placebo + CBT-IExisting treatment, for comparison
Treatment: Cognitive Behavioral Therapy for Insomnia (CBT-I) and Placebo
- Placebo OnlyPlacebo, for comparison
Treatment: Monitoring and Placebo
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- The Effects of Solriamfetol and CBT-I (Alone and in Combination) on Sleep Continuity, Sleepiness, Fatigue, and Performance in Patients With Insomnia Disorder
- Record updated
- 12 May 2026